Synthetic peroxisome proliferator-activated receptor-gamma agonists restore impaired vasorelaxation via ATP-sensitive K+ channels by high glucose.
The present study was designed to examine whether in the human artery, synthetic peroxisome proliferator-activated receptor (PPAR)-gamma agonists restore vasorelaxation as well as hyperpolarization via ATP-sensitive K+ channels impaired by the high concentration of D-glucose and whether the restoration may be mediated by the antioxidant capacity of these agents. The isometric force and membrane potential of human omental arteries without endothelium were recorded. The production rate of superoxide was evaluated using a superoxide-generating system with xanthine-xanthine oxidase in the absence of smooth muscle cells. Glibenclamide abolished vasorelaxation and hyperpolarization in response to levcromakalim. Addition of D-glucose (20 mM) but not L-glucose (20 mM) reduced this vasorelaxation and hyperpolarization. Synthetic PPAR-gamma agonists (troglitazone and rosiglitazone) and/or an inhibitor of superoxide generation (4,5-dihydroxy-1,3-benzene-disulfonic acid, Tiron), but not a PPAR-alpha agonist (fenofibrate), restored vasorelaxation and hyperpolarization in response to levcromakalim in arteries treated with D-glucose. Troglitazone and rosiglitazone, but not fenofibrate, decreased the production rate of superoxide without affecting uric acid generation. These findings suggest that synthetic PPAR-gamma agonists recover the function of ATP-sensitive K+ channels reduced by the high concentration of glucose in human vascular smooth muscle cells and that the effect of these agonists may be mediated in part by their antioxidant capacity.
Department of Anesthesiology, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0012, and Department of Anesthesia, Hiroshima General Hospital, Japan. hkinoshi@pd5.so-net.ne.jp
Hiroyuki
H
Kinoshita
Toshiharu
T
Azma
Hiroshi
H
Iranami
Katsutoshi
K
Nakahata
Yoshiki
Y
Kimoto
Mayuko
M
Dojo
Osafumi
O
Yuge
Yoshio
Y
Hatano
D000255:Adenosine Triphosphate / Q000502:physiology*; D000368:Aged; D019806:Cromakalim / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005947:Glucose / Q000008:administration & dosage* / Q000502:physiology / Q000633:toxicity; D006801:Humans; D008297:Male; D008875:Middle Aged; D047495:PPAR gamma / Q000819:agonists* / Q000502:physiology; D015221:Potassium Channels / Q000502:physiology*; D014652:Vascular Diseases / Q000139:chemically induced / Q000503:physiopathology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology*
D047495:PPAR gamma; D015221:Potassium Channels; D019806:Cromakalim; D000255:Adenosine Triphosphate; D005947:Glucose